TuisEBS • NYSE
add
Emergent Biosolutions Inc
Vorige sluiting
$5,37
Dagwisseling
$5,30 - $5,70
Jaarwisseling
$1,82 - $15,10
Markkapitalisasie
298,31 m USD
Gemiddelde volume
1,15 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NYSE
Marknuus
The Motley Fool
15 uur gelede
Should You Buy the Highest-Yielding Dow Stock After the Market Sell-Off?
0,050%
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 194,70 m | -29,61% |
Bedryfskoste | 140,80 m | -33,40% |
Netto inkomste | -31,30 m | 36,77% |
Netto winsgrens | -16,08 | 10,17% |
Wins per aandeel | 0,05 | 106,49% |
EBITDA | 21,00 m | 255,56% |
Effektiewe belastingkoers | -13,41% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 99,50 m | -10,92% |
Totale bates | 1,39 mjd | -23,78% |
Totale aanspreeklikheid | 906,90 m | -22,74% |
Totale ekwiteit | 482,80 m | — |
Uitstaande aandele | 54,34 m | — |
Prys om te bespreek | 0,60 | — |
Opbrengs op bates | -0,75% | — |
Opbrengs op kapitaal | -0,92% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -31,30 m | 36,77% |
Kontant van bedrywe | -79,90 m | -348,91% |
Kontant van beleggings | 28,60 m | 350,88% |
Kontant van finansiering | 500,00 k | -89,36% |
Netto kontantverandering | -50,80 m | -312,55% |
Beskikbare kontantvloei | -5,54 m | -113,72% |
Meer oor
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Gestig
05 Sep. 1998
Hoofkwartier
Webwerf
Werknemers
900
